A Novel Mouse Model of Campylobacter jejuni Gastroenteritis Reveals Key Pro-inflammatory and Tissue Protective Roles for Toll-like Receptor Signaling during Infection

Campylobacter jejuni is a major source of foodborne illness in the developed world, and a common cause of clinical gastroenteritis. Exactly how C. jejuni colonizes its host's intestines and causes disease is poorly understood. Although it causes severe diarrhea and gastroenteritis in humans, C. jejuni typically dwells as a commensal microbe within the intestines of most animals, including birds, where its colonization is asymptomatic. Pretreatment of C57BL/6 mice with the antibiotic vancomycin facilitated intestinal C. jejuni colonization, albeit with minimal pathology. In contrast, vancomycin pretreatment of mice deficient in SIGIRR (Sigirr−/−), a negative regulator of MyD88-dependent signaling led to heavy and widespread C. jejuni colonization, accompanied by severe gastroenteritis involving strongly elevated transcription of Th1/Th17 cytokines. C. jejuni heavily colonized the cecal and colonic crypts of Sigirr−/− mice, adhering to, as well as invading intestinal epithelial cells. This infectivity was dependent on established C. jejuni pathogenicity factors, capsular polysaccharides (kpsM) and motility/flagella (flaA). We also explored the basis for the inflammatory response elicited by C. jejuni in Sigirr−/− mice, focusing on the roles played by Toll-like receptors (TLR) 2 and 4, as these innate receptors were strongly stimulated by C. jejuni. Despite heavy colonization, Tlr4−/−/Sigirr−/− mice were largely unresponsive to infection by C. jejuni, whereas Tlr2−/−/Sigirr−/− mice developed exaggerated inflammation and pathology. This indicates that TLR4 signaling underlies the majority of the enteritis seen in this model, whereas TLR2 signaling had a protective role, acting to promote mucosal integrity. Furthermore, we found that loss of the C. jejuni capsule led to increased TLR4 activation and exaggerated inflammation and gastroenteritis. Together, these results validate the use of Sigirr−/− mice as an exciting and relevant animal model for studying the pathogenesis and innate immune responses to C. jejuni.


Introduction
Campylobacter jejuni is one of the leading bacterial causes of gastroenteritis in the world. Although responsible for the majority of food-borne bacterial infections in developed countries, and compared to many other common enteric bacterial pathogens, our understanding of the mechanisms underlying C. jejuni's pathogenesis remains poorly defined [1]. One reason for our limited understanding is that C. jejuni appears to utilize unique pathogenic strategies, as it lacks many of the common toxins, effector proteins and virulence factors found in other pathogenic bacteria [1]. For example, cytolethal distending toxin is the only toxin so far identified within Campylobacter strains [1,2] yet its potentially toxic role in vivo remains unclear [2]. Furthermore, a number of bacterial factors such as capsular polysaccharides [3,4], lipooligosaccharides [4] and proteins such as CadF [5], Peb1 [6,7], JlpA [8] and the Campylobacter invasive antigens (Cia) [1,[9][10][11], have all been studied in vitro for roles in C. jejuni cell adhesion and invasion, and in the existing commensal colonization models, however whether they play any role in pathogenicity in vivo is largely unknown.
Indeed, the study of C. jejuni pathogenicity has largely been limited by the lack of relevant and convenient animal models that can be used to replicate human disease [12]. While C. jejuni readily colonizes poultry, it does so in a commensal fashion, causing no disease and thus not providing significant insight into C. jejuni pathogenesis or how the host defends against these microbes. Galleria mellonella larvae, which are a common animal model used for the study of several bacterial pathogens have been applied to C. jejuni [13,14], but their relevance in modeling vertebrate enteric infection is limited. While colostrum-deprived piglets [15], as well as ferrets [16] have been used to model C. jejuni infection with some success, their use is limited by the difficulty obtaining and maintaining these animals, and a lack of immunologic and genetic tools to aid in studying the host response to infection.
Mice would normally provide a preferred infection model system; however, they have repeatedly proven resistant to pathogenic infection by C. jejuni, and many strains are unable to even be reliably colonized [17]. The basis for their resistance to C. jejuni colonization appears to at least partially reflect active competition from the resident intestinal microbiota, thereby preventing C. jejuni from establishing a niche within the murine gut [17][18][19]. Secondly, the murine immune system has proven very tolerant to the presence of C. jejuni and in wild-type (WT) mice, their presence only rarely elicits any overt intestinal inflammation [20,21]. To overcome this tolerance, several groups have tested genetically manipulated mice that develop exaggerated inflammatory responses to bacteria, such as IL-10-deficient (Il-10 2/2 ) mice [20]. While Il-10 2/2 mice can be colonized by C. jejuni, resulting in severe enterocolitis, the loss of IL-10 dramatically alters the murine immune system. As a result, their immune system is unable to effectively clear C. jejuni from the GI tract, leading to chronic colonization rather than the acute infections seen in humans. Moreover the immune systems of Il-10 2/2 mice are so sensitive that the presence of any commensal microbe can potentially trigger spontaneous enterocolitis [21]. The oral gavage and intraperitoneal injections of MyD88-deficient mice, have also been employed for the study of C. jejuni colonization and dissemination in mice [22][23][24], but encounter the reverse limitation of Il-10 2/2 mice, where the immune response is attenuated, allowing for colonization of the intestine or systemic sites with limited host responses. This provides utility for the study of colonization, but not immunity and the development of inflammation in response to C. jejuni.
Recently we showed that mice deficient in Single IgG IL-1 Related Receptor (SIGIRR) exhibit increased susceptibility to infection by two natural enteric bacterial pathogens of mice, namely Citrobacter rodentium and Salmonella enterica serovar Typhimurium [25]. In both mice and humans, SIGIRR is highly expressed by intestinal epithelial cells and acts as a negative regulator of MyD88-dependent signaling, thus acting to dampen signaling by most Toll-like receptors as well as interleukin (IL)-1R [25][26][27]. In the absence of SIGIRR, when these receptors are activated, their downstream signaling is increased, resulting in increased innate inflammatory responses [26,27]. In the context of C. rodentium and S. Typhimurium infections, we found that Sigirr2/2 mice not only developed exaggerated forms of infectious colitis, but they were also infected much more rapidly and with much lower infectious doses than WT mice. This heightened susceptibility was shown to reflect exaggerated antimicrobial responses by Sigirr 2/2 mice that were surprisingly ineffective against pathogens, but instead depleted the competing commensal microbes [25], dramatically reducing the microbiota based resistance to intestinal pathogen colonization.
Based on their heightened susceptibility to natural bacterial pathogens of mice, we examined whether Sigirr 2/2 mice could potentially serve as an infection model for the human pathogen C. jejuni. Although orally delivered C. jejuni were able to sporadically colonize Sigirr 2/2 mice, antibiotic pretreatment was found to facilitate pathogen colonization, leading to acute gastroenteritis in infected Sigirr 2/2 mice. We confirmed that C. jejuni primarily activates the innate receptors TLR2 and TLR4 [28][29][30][31], and found that TLR4 signaling was responsible for most of the inflammatory changes seen during infection. In addition to the requirement for innate signaling, the development of gastroenteritis was also dependent on the activity and pathogenicity of C. jejuni. In infections with C. jejuni mutants deleted for flaA (flagella) [32] or kpsM (capsular polysaccharide) [31,33,34], the ability of C. jejuni to cause gastroenteritis was significantly altered. Together, these results validate the use of Sigirr 2/2 mice as an exciting and relevant animal model for studying innate immune responses to C. jejuni, as well as for the study of pathogenicity factors governing infection by this microbe.

Results
Campylobacter jejuni colonizes and infects the intestines of Sigirr 2/2 mice The murine intestine is thought to be highly resistant to oral infection by C. jejuni, based primarily on the ability of the resident gut microbiota to outcompete any incoming C. jejuni [17,35]. Our experiments support this concept, as we found infrequent and inconsistent C. jejuni colonization of conventionally housed WT C57BL/6 mice following oral inoculation with our wild-type C. jejuni strain 81-176 (10 7 CFU) (data not shown). To overcome this barrier to colonization, we pretreated WT C57BL/6 mice with vancomycin by oral gavage prior to inoculation with C. jejuni. Previous research by Russell et al. [36] showed that oral vancomycin treatment depleted Bacteroidetes and Clostridia from the intestines of mice while promoting the overgrowth of

Author Summary
Research into the key virulence strategies of the bacterial pathogen Campylobacter jejuni, as well as the host immune responses that develop against this microbe have, in many ways, been limited by the lack of relevant animal models. Here we describe the use of Sigirr deficient ( 2/2 ) mice as a model for C. jejuni pathogenesis. Not only do Sigirr 2/2 mice develop significant intestinal inflammation in response to colonization by C. jejuni, but the ability of this pathogen to trigger gastroenteritis was dependent on key virulence factors. We also found that the induction of the inflammatory and Th1/Th17 immune responses to infection in these mice depended on specific Toll-like receptors, principally TLR4, which we identified as the main driver of inflammation. In contrast, TLR2 signaling was found to protect mucosal integrity, with Tlr2 2/2 / Sigirr 2/2 mice suffering exaggerated mucosal damage and inflammation. Notably, we found that C. jejuni's capsule helped conceal it from the host's immune system as its loss led to significantly increased activation of host TLRs and exaggerated gastroenteritis. Our research shows that the increased sensitivity of Sigirr 2/2 mice can be used to generate a unique and exciting model that facilitates the study of C. jejuni pathogenesis as well as host immunity to this enteric pathogen.
Lactobacilli [36]. Vancomycin pretreatment has also been shown to promote S. Typhimurium colonization and colitis in a fashion similar to streptomycin pretreatment [37]. Following oral inoculation with C. jejuni, we found the vancomycin pretreated WT mice exhibited consistent and robust pathogen colonization in their ceca ( Figure 1a) and colons ( Figure S1a). Despite their high levels of colonization, minimal signs of inflammation were observed (Figure 1b and c), consistent with previously published analyses of C. jejuni-colonized immunocompetent mice.
Considering that Sigirr 2/2 mice exhibit impaired colonization resistance against several murine enteric bacterial pathogens, we tested their susceptibility to C. jejuni infection/colonization. We again saw only sporadic colonization in some mice, but in contrast to WT mice, we also saw occasional signs of intestinal inflammation and other forms of pathology but the results were insufficiently reproducible to provide a reliable model (data not shown). We therefore tested the impact of pretreating Sigirr2/2 mice with vancomycin, as previously described for WT mice. We noted that vancomycin induced a similar change in the intestinal microbiota of Sigirr 2/2 mice as we had found for WT mice ( Figure  S2). Four hours after vancomycin pretreatment, we orally infected Sigirr 2/2 mice along with WT mice with approximately 10 7 CFU of C. jejuni 81-176. We euthanized the mice at 3 and 7 days postinfection, assessing pathogen burden in the cecum (Figure 1a), Figure 1. Colonization of WT and Sigirr2/2 mice by C. jejuni 81-176, 3 and 7 DPI. (A) High numbers (,10 9 CFUs/g) of C. jejuni were recovered at both 3 and 7 DPI from the ceca of infected mice that were pre-treated with 5 mg of vancomycin. No statistically significant differences in numbers were found between WT and Sigirr 2/2 mice as indicated by a t-test, p.0.05. n = 10 or 11 WT mice, and 12 or 13 Sigirr 2/2 mice for 3 and 7 DPI respectively. (B) H&E stained, formalin-fixed histological sections of ceca recovered from WT or Sigirr 2/2 mice 3 and 7 DPI. Upper panels are 6100 magnification, while lower panels are 6400 magnification. (C) Pathological scoring was done by two blinded observers, using H&E stained, formalin-fixed cecal tissue sections. Each condition represents a minimum of three separate experimental replicates, with 2-3 mice per experiment for a total of 6-9 mice per group. Control mice were used as a reference and consisted of 3 uninfected mice, pre-treated with a single dose of 5 mg/ 100 ml vancomycin, and euthanized 3 days post-treatment. WT (B6) mice did not exhibit any significant signs of inflammation, while Sigirr 2/2 and Tlr2 2/2 /Sigirr 2/2 mice showed a significant increase relative to the uninfected Sigirr 2/2 control, both 3 and 7 DPI. Tlr4 2/2 /Sigirr 2/2 mice showed a statistically significant increase, relative to control mice at 3 DPI only, but even at 3 DPI, were significantly less than either Sigirr 2/2 and Tlr2 2/2 / Sigirr 2/2 mice. Statistical significance was determined using a two-way ANOVA and a Bonferroni post-test (NS p.0.05, *p,0.05, ** p,0.01, *** p, 0.001, **** p,0.0001). doi:10.1371/journal.ppat.1004264.g001 colon, ileum, mesenteric lymph nodes (MLN), spleen and feces (Figure S1a-e). Both WT and Sigirr 2/2 mice were quickly colonized, with both strains of mice reaching cecal colonization levels of approximately 10 9 CFU/g within 3 days. In Sigirr 2/2 mice, colonization numbers usually peaked within 7-9 days, and began to drop significantly by 2-3 weeks post-infection, with low levels of C. jejuni (,10 4 CFUs/g) found beyond 3 weeks ( Figure  S3a). WT mice maintained high and relatively unchanging pathogen burdens for at least 25 days ( Figure S3a). Colonization in the colon was similar to the cecum, whereas relatively fewer C. jejuni were recovered from the ileum ( Figure S1b). Fecal samples taken just prior to euthanization, and throughout the infection, proved to be largely representative of the colonization of both the cecum and colon, with the numbers more closely resembling the numbers recovered from the colon (Figure S1e and f). C. jejuni were also occasionally recovered in low numbers from the MLN and rarely from the spleen ( Figure S1c, d), indicating that even with a high pathogen burden in the gut, C jejuni did not readily go systemic.
Despite carrying similar pathogen burdens, the macroscopic pathology resulting from C. jejuni colonization was dramatically more severe in the Sigirr 2/2 mice as compared to WT mice. Although neither mouse strain exhibited significant weight loss (. 10%) ( Figure S3b) or other severe signs of morbidity, the ceca and proximal colons of the Sigirr 2/2 mice were overtly inflamed and often devoid of stool contents. In mice at the height of infection, the stool itself often became noticeably softer and sticky. Significant enlargement of the mesenteric lymph nodes was also noted in infected Sigirr 2/2 mice ( Figure S4). In comparison, control mice treated with vancomycin, but not receiving C. jejuni, exhibited no significant signs of intestinal pathology 3 or 7 days post antibiotic treatment (Figure 1c and data not shown). As expected, histology revealed few, if any, signs of cecal inflammation in WT mice at 3 DPI (Figure 1b), and only very mild signs of inflammation at 7 DPI, despite their heavy pathogen burden. In contrast, the cecal pathology and inflammation observed in infected Sigirr 2/2 mice was very severe at both 3 and 7 DPI, including submucosal edema, crypt hyperplasia and widespread immune/inflammatory cell infiltration (Figure 1c). In some cases, the Sigirr 2/2 mice developed focal cecal ulcers, accompanied by bleeding into the lumen (Figure 1b). The severe damage was focused within the cecum and proximal colon, with only minimal signs of inflammation appearing elsewhere in the intestine.
When we measured gene transcript levels of several key cytokines, we found that despite the lack of overt inflammation in the infected WT mice, they still showed upregulated gene transcript levels for a number of cytokines compared to uninfected mice, most notably TNFa, indicating that the WT mice were not completely unresponsive to the presence of C. jejuni. However these responses were insufficient to trigger overt signs of inflammation ( Figure 2). The infected Sigirr 2/2 mice also showed elevated cytokine gene transcripts at levels significantly higher than those seen in WT mice. Notably, at both 3 and 7 DPI, the Sigirr 2/2 mice showed significantly higher mRNA levels for IL-17A, TNF-a and Interferon gamma (IFNc), indicative of a stronger inflammatory response. We also observed higher transcription of the neutrophil chemoattractant KC, as well as the cytokines IL-1b, IL-18 and IL-22, though the variability between mice prevented the demonstration of statistical significance.
C. jejuni localizes within the cecal crypts of Sigirr 2/2 mice To better define the cause of the exaggerated tissue pathology suffered by infected Sigirr 2/2 mice, we explored the localization of the colonizing C. jejuni and whether it differed with that in WT mice. Staining for C. jejuni in intestinal tissue sections of WT mice at both 3 and 7 DPI revealed the bacteria were largely limited to the intestinal lumen, with rare C. jejuni found in only 26.5% (70/ 264) of crypts. We also noted C. jejuni accumulating in the mucus layer, whereas relatively few microbes were found in direct contact with the intestinal epithelium or penetrating the cecal or colonic crypts ( Figure 3). Conversely, in the Sigirr 2/2 mice, C. jejuni were not only found within the intestinal lumen and the mucus layer, but large numbers were also seen penetrating deep within cecal and colonic crypts ( Figure 3). In these mice, 56.2% (82/146) of crypts were found to be heavily colonized by C. jejuni.
C. jejuni adhere to as well as invade the intestinal epithelium of Sigirr 2/2 mice When we examined the localization of C. jejuni within Sigirr 2/2 tissues more closely, we observed that large numbers of the bacteria were in direct contact with the intestinal epithelium, particularly within crypts ( Figure 3a). By co-staining for C. jejuni antigens along with either b-actin or cytokeratin 19, we could clearly visualize the cytoskeleton of the epithelial cells, relative to the localization of the C. jejuni. In addition to adherent C. jejuni, we also visualized C. jejuni co-localizing with and potentially within the epithelial layer ( Figure 4a). To address whether these C. jejuni were intracellular, we examined the stained cells using confocal microscopy, to determine whether they were in fact internalized (Figure 4b and c). Indeed, in the X, Y and Z axes, labeled C. jejuni were present inside epithelial cells, often organized into spherical foci, suggesting their localization within a vesicle or phagosome (Figure 4b and c). Previous studies have identified Lamp-1, a lysosome-associated membrane protein as a marker for intracellular S. Typhimurium containing vacuoles [38,39] as well as for phagosomes containing C. jejuni [40,41] inside cultured epithelial cells. To address whether a similar structure was present in vivo, we stained for Lamp-1 [42], and clearly observed internalized C. jejuni within epithelial cells to be surrounded by Lamp-1 positive membrane structures (Figure 4d). Although the precise numbers of internalized C. jejuni present in a tissue section varied, we observed intracellular C. jejuni in all infected Sigirr 2/2 mice tested.

Campylobacter virulence factors are necessary for successful infection
While our data showed that SIGIRR deficiency facilitated the ability of C. jejuni to adhere to and infect intestinal epithelial cells in vivo, resulting in overt gastroenteritis, it was unclear whether the resulting pathology depended on C. jejuni pathogenicity factors. To test this, we inoculated our WT and Sigirr 2/2 mice with two previously well-characterized C. jejuni mutants: DkpsM and DflaA, as well as the complemented strains for each mutant. The kpsM gene encodes the permease of the capsule polysaccharide ABC transporter. This gene deletion results in the loss of the entire capsule surrounding the microbe, which is thought to be a key virulence-associated cellular structure [33,43]. The DflaA flagellar mutant lacks the primary flagellin protein, and although expression of the secondary FlaB flagellin continues, the result is a truncated flagellum and a significant loss of motility [44]. This phenotype has been previously associated with an inability to invade epithelial cells in vitro [32], and defective colonization of chicks [45].
We initially observed significant shifts in colonization for each of the mutant strains tested. Whereas wild-type C. jejuni readily colonized the intestines of Sigirr 2/2 mice, each of the mutant strains suffered colonization defects (Figure 5a and b, Figure S5a). The DkpsM mutant was significantly impaired at 3 DPI, but approached WT numbers by 7 DPI. The complemented version of this mutant was significantly less impaired for colonization at 3 DPI, and more closely resembled the colonization potential of the wild-type strain. Conversely, the DflaA flagellar mutant was severely impaired in colonization and was completely lost from the intestine by 3 DPI and remained absent at 7 DPI. The mutant and complemented strains were also assessed for growth in vitro, and neither mutant exhibited growth defects ( Figure S5b).
In terms of pathology, each mutant exerted a substantially different effect on the gastroenteritis seen in infected Sigirr 2/2 Figure 2. Cytokine production in infected mice. (A-H) RT-qPCR conducted on RNA extracted from the ceca of uninfected control or infected mice. Controls are the pooled results of 9, vancomycin pre-treated, but uninfected mice, euthanized 3 days post-treatment. All infected mice represent the average results of 3 independent experiments, each of which include the pooled RNA of 2-3 mice, for 6-9 mice total for each mouse strain, euthanized either 3 or 7 DPI. Statistical significance was determined using a One way ANOVA with a Bonferroni post-test. * p,0.05 relative to WT (B6) or Sigirr 2/2 uninfected control mice. ** p,0.05 relative to the infected WT (B6) mice euthanized on the same DPI in addition to the uninfected control mice. doi:10.1371/journal.ppat.1004264.g002  mice. As might be expected given the severe colonization defect, the DflaA mutant did not elicit any significant inflammation or pathology (Figure 5c). In contrast, despite the DkpsM mutant suffering delayed colonization, it still caused overt gastroenteritis at 7 DPI that was in fact significantly worse than that seen following infection with wild-type C. jejuni (Figure 5d). To explore the basis for this exaggerated pathology, we next examined how the immune system is stimulated during in vivo C. jejuni infection.
TLR2 and TLR4 are key players in the inflammatory response to C. jejuni Previous research has shown that C. jejuni activates several Tolllike receptors (TLR) including TLR2 and TLR4, and that TLR activation may play a key role in regulating host inflammatory responses to C. jejuni [21,[28][29][30][31]. To confirm that our wild-type C. jejuni strain (81-176) stimulated these TLRs, we used HEK-TLR2 and HEK-TLR4 reporter cells with a NF-kB/AP-1 inducible reporter-SEAP to measure stimulation of TLR2 and TLR4 in vitro. We observed significant stimulation of both receptors by C. jejuni 81-176, consistent with previously published results by Maue et al. [31] (Figure 6). To explore the impact that this activation might play in our infection model, we infected Tlr2 2/2 /Sigirr 2/2 and Tlr4 2/2 /Sigirr 2/2 mice. Although the Tlr4 2/2 /Sigirr 2/2 mice were heavily colonized by C. jejuni, (Figure 7a) they proved largely unresponsive to the pathogen, exhibiting few if any signs of the gastroenteritis seen in infected Sigirr 2/2 mice (Figure 7b). Notably, these mice showed little response to infection even at the gene transcriptional level. While these mice did exhibit significantly elevated expression of TNFa and IFNc at 3 DPI, by 7 DPI, their expression of these, and other pro-inflammatory cytokines had decreased to levels similar to those in uninfected controls ( Figure 2). Conversely, the Tlr2 2/2 /Sigirr 2/2 mice were significantly more sensitive to C. jejuni infection, even compared to infected Sigirr 2/2 mice (Figure 7b and c), suffering exaggerated gastroenteritis by 3 DPI that involved worsened edema, crypt hyperplasia and inflammatory cell infiltration, including large numbers of neutrophils. Moreover, there were frequent signs of ulceration in these mice, along with loss of crypt structure and overall loss of epithelial integrity. Pathological scoring of tissues confirmed that the damage suffered by the Tlr2 2/2 /Sigirr 2/2 mice was significantly more severe than that seen in WT mice, and even more than that of Sigirr 2/2 mice at 3 DPI, though the severity of their inflammation was reduced by 7 DPI, leaving it similar in severity to that seen in Sigirr 2/2 mice at this time point. Consistent with their severe pathology, we observed a dramatic induction of inflammatory cytokine genes within the ceca of Tlr2 2/2 /Sigirr 2/2 mice at 3 DPI ( Figure 2). This included significantly elevated levels of IL-1b, IL-6, IFNc, KC, IL-22, IL17 and TNF-a gene transcripts, particularly at 3 DPI, although expression of many of these cytokines dropped by 7 DPI (Figure 2). Interestingly, the localization of C. jejuni was similar amongst all three SIGIRRdeficient mouse strains, with the C. jejuni seen in large numbers deep within cecal and colonic crypts, as well as inside intestinal epithelial cells (Figure 7c and data not shown). C. jejuni colonization of crypts in the Tlr2 2/2 /Sigirr 2/2 and Tlr4 2/2 /Sigirr 2/2 strains was comparable to the Sigirr 2/2 mice, with 41.7% (50/120) and 47.1% (66/140) of observed crypts being positively colonized, often with high numbers of bacteria in each crypt (Figure 7c). This indicates that the significant differences in pathology amongst the three SIGIRR deficient mouse strains were governed by the stimulation of the TLRs instead of by changes in the localization of the bacteria. We also assessed Tlr2 2/2 and Tlr4 2/2 single mutants for colonization and inflammation. Once again, pathogen burden was not affected by the mouse strain so long as it was accompanied by vancomycin pretreatment (data not shown). Unsurprisingly, Tlr4 2/2 were completely unresponsive to the presence of C. jejuni, exhibiting no inflammation ( Figure S6). Tlr2 2/2 were much less responsive than Tlr2 2/2 /Sigirr 2/2 mice, but did show modest signs of inflammation by 7 DPI ( Figure S6). Together, these results demonstrate that the majority of the inflammation seen in this model is driven by TLR4, whereas TLR2 signaling appears to play a protective role.
TLR2 and TLR4 are activated to a higher degree by mutant DkpsM C. jejuni Based on previous data published by Rose et al. [34] and Maue et al. [31] we expected the capsule to play a role in modulating TLR responses to C. jejuni. To further explore the impact of TLR signaling during C. jejuni infection, we tested the effect of the DkpsM mutant on our TLR2 and TLR4 reporter cell lines. The DkpsM mutant stimulated both TLR2 and TLR4 to a significantly higher degree than the wild-type 81-176 strain with the complemented DkpsM+kpsM strain completely or nearly completely rescuing the mutant phenotype ( Figure 6). To test whether these results translated to increased inflammation in vivo, we infected our different mouse strains with this mutant. As shown in Figure 8a, the DkpsM mutant elicited a very significant inflammatory response in the Sigirr 2/2 mice by 7 DPI. Moreover, it also caused exaggerated inflammation and pathology in Tlr2 2/2 /Sigirr 2/2 Figure 6. TLR2 and 4 reporter assays. HEK-Blue hTLR2 (A) and HEK-Blue hTLR4 (B) reporter cell lines were exposed for 4 hrs to either live and heat-killed wildtype C. jejuni 81-176, DkpsM or DkpsM+kpsM. The wild-type C. jejuni stimulates both TLR2 and TLR4 in a dose-dependent fashion. The DkpsM mutant significantly increased the signaling by both TLR2 and TLR4, as indicated by the assay, with the increase in stimulation also being in a dose-dependent manner, except for the TLR4 assay where the readers were near the maximum for both the 20 and 200 MOI readings. The complemented DkpsM+kpsM strain completely restored the wild-type phenotype with TLR2 and mostly restored the phenotype with TLR4. Values represent the mean of three independent experiments and statistical significance was determined by a two-way ANOVA with a Bonferroni post-test. (* p,0.05, ** p,0.01, *** p,0.001, **** p,0.0001). doi:10.1371/journal.ppat.1004264.g006 Figure 7. Pathology of Tlr2 2/2 /Sigirr 2/2 and Tlr4 2/2 /Sigirr 2/2 mice infected with C. jejuni. (A) High numbers (,10 9 CFUs/g) of C. jejuni were recovered from the ceca of infected Tlr2 2/2 /Sigirr 2/2 and Tlr4 2/2 /Sigirr 2/2 mice that were pre-treated with 5 mg/ml of vancomycin. No statistically significant differences in numbers were found between WT, Sigirr 2/2 , Tlr2 2/2 /Sigirr 2/2 and Tlr4 2/2 /Sigirr 2/2 mice as indicated by t-test, p.0.05. n = 7-9 mice per condition. (B) H&E stained histological sections of ceca recovered from Tlr2 2/2 /Sigirr 2/2 and Tlr4 2/2 /Sigirr 2/2 mice 3 or 7 DPI. Panels on the left are 6100 magnification, while the right panels are 6400 magnification. Very severe inflammation is apparent in the Tlr2 2/2 /Sigirr 2/2 mice both 3 and 7 DPI. Few signs of inflammation are evident in the Tlr4 2/2 /Sigirr 2/2 mice 3 DPI, and no signs of inflammation are apparent 7 DPI. (C) Immunofluorescence staining of formalin-fixed tissue sections of ceca obtained from C. jejuni-infected Tlr2 2/2 /Sigirr 2/2 and Tlr4 2/2 /Sigirr 2/2 mice 3 DPI at 6200 magnification. Sections are stained for DAPI (blue), b-actin (green), and C. jejuni (red). C. jejuni is clearly visible in the crypts of the Tlr4 2/2 /Sigirr 2/2 mice, but with few signs of inflammation. The Tlr2 2/2 /Sigirr 2/2 mice lose much of their crypt structure, due to epithelial cell loss and immune cell infiltration, however, C. jejuni is still clearly visible intermixed with immune cells in what remains of the cecal crypts. doi:10.1371/journal.ppat.1004264.g007 mice as compared to the effects of wild-type C. jejuni, yet once again there was little response in the Tlr4 2/2 /Sigirr 2/2 mice (Figure 8a). The localization of the DkpsM mutant in vivo was similar to that of wild-type C. jejuni, as it was frequently found in direct contact with the epithelium and deep within crypts (Figure 8b). These results were confirmed when cytokine transcript levels were assessed ( Figure S7) Together, these data support previously published in vitro results [31,34], and for the first time demonstrates that the C. jejuni capsule limits the host innate responses to this pathogen during the course of infection.

Discussion
A lack of animal models, and in particular mouse models that replicate the gastroenteritis caused by C. jejuni infection in humans, has long been an impediment to the study of C. jejuni pathogenesis. Moreover, improved preclinical models of C. jejuni infection are a necessity to better define those host factors that protect against this pathogen. Here we demonstrate that the antibiotic vancomycin facilitates C. jejuni's colonization of the mouse intestine, presumably through the removal of commensal microbes that promote resistance against C. jejuni colonization. Moreover, our studies validate the use of vancomycin pretreated Sigirr 2/2 mice as a model for C. jejuni infection and pathogenesis, as these mice develop acute gastroenteritis following infection. We were able to define the role of innate signaling in this model through the testing of Tlr2 2/2 /Sigirr 2/2 and Tlr4 2/2 /Sigirr 2/2 mice as well as clarify specific aspects of C. jejuni pathogenesis through the testing of mutant strains. Taken together, we demonstrate that by modulating the gut microbiota as well as the innate sensitivity of the murine intestine, we have been able to develop a reliable and exciting new animal model of C. jejuni infection.
WT mice, including the C57BL/6 strain used in this study, have in the past proven resistant to infection by C. jejuni, limiting their utility as an infection model [17,35]. This limitation in the ability to colonize mice has been linked to the intestinal microbiota, and its ability to out-compete invading C. jejuni. Previous studies have explored how to overcome this barrier by using mice with a ''humanized'' microbiota [17], as well as germ-free mice and mice carrying a limited microflora [19,21,46]. In the current study, we used an approach successfully employed with other bacterial pathogens [37], using a single pre-treatment of the antibiotic Figure 8. Colonization and pathology of Sigirr 2/2 and TLR-deficient mice by C. jejuni DkpsM in vivo. (A) H&E stained histological sections of ceca recovered from Sigirr 2/2 , Tlr2 2/2 /Sigirr 2/2 and Tlr4 2/2 /Sigirr 2/2 mice, colonized with C. jejuni DkpsM 7 DPI, at 1006 magnification. Very severe inflammation is evident in the Sigirr 2/2 and Tlr2 2/2 /Sigirr 2/2 mice, however once again, no significant pathology was evident in the Tlr4 2/2 / Sigirr 2/2 mice. (B) Immunofluorescence of Sigirr 2/2 mice infected by C. jejuni DkpsM, 7 DPI. Sections are stained for DAPI (blue), b-actin (green), and C. jejuni (red). Sigirr 2/2 mice exhibit significant neutrophil infiltration, hyperplasia, and C. jejuni DkpsM is clearly visible in large masses within the cecal crypts. (C) Pathological scoring was done by two blinded observers, using H&E stained, formalin-fixed cecal tissue sections. Each condition represents a minimum of three separate experimental replicates, with 2-3 mice per experiment. Control mice were used as a reference and consisted of 3 uninfected mice, pre-treated with a single dose of 5 mg/100 ml vancomycin, and euthanized 3 days post-treatment. Only Sigirr 2/2 and Tlr2 2/2 / Sigirr 2/2 mice at 7 DPI showed a significant increase in pathology (****p,0.0001), relative to the uninfected Sigirr 2/2 control. The Tlr2 2/2 /Sigirr 2/2 mice also exhibited statistically significantly higher inflammation at 7 DPI relative to Sigirr 2/2 mice also at 7 DPI (**p,0.001). In contrast, none of the mouse strains at 3 DPI showed any statistically significant increase in pathology, relative to control mice. Statistical significance was determined using a two-way ANOVA and a Bonferroni post-test. doi:10.1371/journal.ppat.1004264.g008 vancomycin to disturb the murine microbiota sufficiently to allow C. jejuni to establish in the intestine. This colonization was, however, insufficient to produce an effective model of inflammation, as the colonized mice remained highly tolerant to the presence of C. jejuni, displaying few if any signs of inflammation, even in the presence of a high pathogen load.
Our previous studies identified Sigirr 2/2 mice as displaying increased susceptibility to infection by the natural mouse pathogens S. Typhimurium and C. rodentium in terms of both the severity of disease as well as pathogen burden [25]. Normally highly expressed by the intestinal epithelium, SIGIRR acts to dampen signaling through MyD88-dependent receptors such as most TLRs as well as IL-1R [26]. Thus SIGIRR expression is thought to help maintain the relative innate hypo-responsiveness of the intestinal epithelium. While the absence of SIGIRR does not lead to spontaneous intestinal inflammation, it does leave the epithelium more sensitive to microbial stimulation through TLRs. Previous studies identified TLR2 and TLR4 as being stimulated by C. jejuni in vitro [31,34] and our study confirmed these two TLRs actively respond to C. jejuni. Moreover, TLR4 has been identified as being a major driver of inflammation in C. jejuni-infected IL-10 2/2 mice [21] and the present study found the gastroenteritis seen in infected Sigirr 2/2 mice is almost completely TLR4 dependent. In contrast, TLR2 signaling was found to protect the intestine from exaggerated injury, potentially by promoting responses in the epithelium that limit the damage caused by the TLR4 driven inflammation.
Taken together, there are several advantages to the use of the Sigirr 2/2 mouse over other models of C. jejuni infection. While C. jejuni readily colonizes the intestines of newborn chickens, it only does so in a commensal fashion, thus providing little insight into its pathogenesis or how it triggers gastroenteritis. While neonatal piglet and ferret models have been used successfully as models for infection [15,16], both have significant limitations as these animals are difficult to acquire as well as handle, and there are few immunological or genetic tools available for these species. To circumvent these issues, mice remain one of the preferred animal species for use in research, but their resistance to C. jejuni colonization and disease has limited their utility in the field. The most successful mouse model of C. jejuni infection to date has been the Il-10 2/2 mouse, which has several features in its favor, including a very strong and reproducible inflammatory response [20,21,46]. However, it also suffers from several complications, notably the propensity of the Il-10 2/2 mice to develop spontaneous colitis as a reaction against their own microbiota [47], forcing researchers to use more inconvenient and costly germ-free conditions [21,46]. Additionally, IL-10 has been shown to be a key cytokine in the resolution for inflammation following infection, meaning that C. jejuni infection in IL-10 2/2 mice is ultimately chronic and lethal to the mice, as opposed to the acute, selflimiting infection observed in humans.
Our use of Sigirr 2/2 mice addresses most of these issues. When orally inoculated with a relatively low dose of C. jejuni, the vancomycin pre-treatment allowed for reliable colonization, while only causing a temporary disruption in the microbiota. Although our previous research has identified a higher inflammatory ''tone'' in the Sigirr 2/2 mice, characterized by slightly higher expression of several pro-inflammatory cytokines [25], the Sigirr 2/2 mice themselves do not develop spontaneous colitis in response to their own microbiota as often occurs in IL-10 2/2 mice. When infected with C. jejuni they developed only an acute gastroenteritis, in keeping with the clinical effects of C. jejuni infection. Moreover, the gastroenteritis bears several hallmarks of C. jejuni infection, including prominent neutrophil infiltration into the infected tissues and lumen. Our assessment of Tlr4 2/2 /Sigirr 2/2 mice determined that the vast majority of the inflammation seen in this model is TLR4 dependent, which is in agreement with previous observations in gnotobiotic IL-10 2/2 mice [21].
In contrast to the modest responses seen in infected Tlr4 2/2 / Sigirr 2/2 mice, when we infected Tlr2 2/2 /Sigirr 2/2 mice, we observed a significantly exaggerated and accelerated form of gastroenteritis, especially at the early stages of infection (3 DPI). Correspondingly, these mice suffered increased pathology, including widespread loss of epithelial integrity, loss of crypt structure and frequent ulceration. This was accompanied by substantially increased pro-inflammatory cytokine expression. The most severe pathology was apparent at 3 DPI, with both cytokine expression and pathology dropping substantially by 7 DPI to the point where it was no longer significantly more severe than that seen in Sigirr 2/2 mice. These findings are intriguing as they suggest that TLR2 plays a protective role, at least during the early stages of C. jejuni infection. Previous studies have identified roles for TLR2 in the maintenance of epithelial tight junctions in the intestine, for example by increasing the production of Trefoil Factor 3 [48], along with other barrier protective proteins [49,50]. As recently described by our laboratory, innate inflammatory responses in the GI tract appear to reflect a tenuous balance between damaging inflammatory signals and concurrent protective or tolerance inducing innate responses that limit the resulting tissue damage. It appears this is also the case during C. jejuni infection, with TLR2 playing a key role in limiting damage suffered by the host as its immune system tries to clear C. jejuni from the intestine [51].
Aside from exploring the host response to infection, an optimal C. jejuni infection model must be able to distinguish subtle aspects of C. jejuni pathogenicity. To address this issue, we infected our Sigirr 2/2 mice with C. jejuni strains lacking the ability to form a capsule, as well as a flagellar mutant. Regarding the DflaA flagellar mutant, previous studies have found C. jejuni mutants that are nonmotile or suffer reduced motility are unable to effectively colonize the intestines of chicks [45], piglets [15], or wildtype mice [52,53]. We therefore expected the DflaA strain to be impaired in colonization, and indeed, the DflaA mutant was unable to colonize the Sigirr 2/2 mice or cause any level of gastroenteritis. Precisely why this mutant was unable to colonize is an interesting question. We predominantly observe C. jejuni colonization in the mucus layer and into the crypts. Both leaving the lumen of the intestine and migration through the mucus layer would presumably require fully motile bacteria. It would appear that the inability of C. jejuni with reduced motility to reach and move through these niches results in a loss of colonization potential, even in mice with reduced microbiota competition.
In the case of the DkpsM mutant, it exhibited a delay in colonization as assessed at 3 DPI, but by 7 DPI, its pathogen load had increased to levels similar to WT C. jejuni. This could indicate a greater sensitivity of this mutant to the innate defenses in the gut. Previous work has already linked the loss of capsule to increased sensitivity to environmental factors such as osmotic stress [54], as well as antimicrobial factors [55]. However, the reduced colonization of DkpsM was transient, as the mutant quickly recovered to WT levels. Despite this initial delay, the DkpsM strain was able to elicit significantly more severe gastroenteritis than that seen with the wild-type C. jejuni. When we tested the DkpsM mutant in our in vitro reporter system, we found it stimulated both TLR2 and TLR4 to a significantly higher degree than that seen with WT C. jejuni. This result is consistent with previous findings [31,34], suggesting a role for the capsule in reducing the exposure of pathogenic bacteria to the host's immune system by masking some of the TLR activating PAMPs. For example, Rose et al.
determined that the presence of a capsule reduces cytokine expression by dendritic cells exposed to C. jejuni in vitro [34], and a similar observation was made by Maue et al. in an epithelial reporter cell line [31]. Here, for the first time in vivo, we demonstrate that the capsule does help conceal C. jejuni from the host's immune system, potentially as a means to limit host driven defenses as well as perhaps limit collateral tissue damage to the host.
One of the most intriguing findings from our study involved the localization of C. jejuni in the intestines of the Sigirr 2/2 mice. In WT mice, C. jejuni were found predominantly in the lumen, along with a clustering at the luminal surface of the mucus layer. Notably, relatively few C. jejuni were found in direct contact with the cecal or colonic epithelium, and few were seen penetrating the crypts. In contrast, in the Sigirr 2/2 mice we found large numbers of C. jejuni, not only within this mucus layer, but also penetrating and accumulating in large numbers at the base of the intestinal crypts. Similar observations were made in infected Tlr2 2/2 / Sigirr 2/2 mice, although in these mice, the exaggerated damage they suffered often left C. jejuni mixed within sloughed epithelial cells as well as phagocytosed inside neutrophils at sites of ulceration. This phenotype of crypt colonization was not restricted to mice developing severe inflammation, since Tlr4 2/2 /Sigirr 2/2 mice also displayed large numbers of bacteria within their cecal crypts. Thus the factor within Sigirr 2/2 mice that permits C. jejuni to colonize the crypts is not a result of overt inflammation, in contrast to recent studies of S. Typhimurium colonization of the murine intestine [56], but may be due instead to more subtle differences in the microenvironment of the crypts.
Aside from penetrating intestinal crypts, we also determined that C. jejuni could invade the intestinal epithelial cells of our Sigirr 2/2 mice. Intracellular C. jejuni were observed in both the cecum and colon of infected mice, and were usually seen in the more mature epithelial cells, at the top of crypts rather than at their base. Co-staining with b-actin or cytokeratin 19 confirmed that the C. jejuni were inside epithelial cells, while staining for LAMP-1 localized the internalized bacteria within LAMP-1 positive vesicles. Interestingly, the presence of intracellular C. jejuni did not on its own drive significant inflammation as internalized bacteria were also found in infected Tlr4 2/2 / Sigirr 2/2 mice, which exhibited no significant signs of inflammation. This indicates that intracellular C. jejuni can exist without causing overt inflammation or pathology; however, it remains possible that this cellular invasion can play a triggering role for the overt inflammation seen in infected Sigirr 2/2 and Tlr2 2/2 /Sigirr 2/2 mice.
Together, these studies provide new insight into the pathogenicity of C. jejuni, and how colonization by this microbe triggers an inflammatory reaction by its host. In conventional WT mice, the commensal microbiota provide colonization resistance against C. jejuni by outcompeting the invading pathogen. Through vancomycin treatment, we were able to readily disrupt this protection, but the WT mice remained substantially tolerant to the presence of C. jejuni, resulting in almost no inflammatory response. In contrast, in the absence of SIGIRR, the murine immune system proved dramatically more responsive to C. jejuni, potentially by increasing the sensitivity of epithelial expressed TLRs. Overall, the degree of inflammation that developed in the infected intestines of the Sigirr 2/2 mice appeared to correlate with the invasion by C. jejuni of the intestinal crypts, and appeared almost totally dependent on the actions of TLR4. In conclusion, we present the Sigirr 2/2 mouse as an effective and exciting new model for the study of C. jejuni infection and pathogenesis. We speculate that our demonstration that Sigirr 2/2 mice can indeed be infected in a relevant fashion by C. jejuni will provide an impetus for further study, to better elucidate both the host factors and pathogenesis that drive gastroenteritis.

Bacterial strains and growing conditions
The wild-type C. jejuni strain used in this study is the commonly used 81-176 lab strain and all mutant and complemented strains were constructed on this background. The bacteria were routinely grown on Mueller-Hinton agar plates or broth, supplemented with the selective antibiotics Chloramphenicol and/or Kanamycin as required. Additionally, during mutant and complement construction, plates and broth were routinely supplemented with vancomycin (10 mg/mL) and trimethoprim (5 mg/mL) to prevent contamination. Cultures were routinely grown under microaerophilic conditions using anaerojars and CampyGen sachets (Oxoid) at 42uC.

C. jejuni mutant and complement construction
To construct deletion mutants in the genes flaA and kpsM, each gene was PCR amplified with iProof (Bio-Rad) from C. jejuni 81-176 with the appropriate primers listed in Table S1. The product was polyA tailed and ligated to pGEM-T (Promega). Inverse PCR was performed on the resulting plasmid, deleting 1248 bp or 514 bp from the flaA or kpsM genes respectively. The flaA and kpsM inverse PCR products were digested with KpnI and SpeI, or KpnI and XbaI respectively, then ligated to the non-polar kanamycin resistance cassette (aphA-3) digested out of pUC18K-2 [57]. The construct was verified by sequencing and naturally transformed to C. jejuni 81-176. Mutant strains were selected by kanamycin resistance, and verified by sequencing.
To complement each of these mutants, flaA or kpsM was PCR amplified from C. jejuni 81-176 genomic DNA, digested with SpeI and MfeI, or XbaI and MfeI respectively, and inserted into pRRC [58] digested with XbaI and MfeI. The resulting construct was verified by PCR and sequencing, and naturally transformed into the corresponding mutant. Complemented strains were selected on chloramphenicol and verified by PCR and sequencing.
Additional confirmation of the phenotypes of both mutant and complemented strains were undertaken to ensure they corresponded to previously published data for these mutants. The DflaA mutant and complement were tested for motility, indicating the mutant was only approximately 25% as motile as the WT or complemented strain [59]. The DkpsM mutant was tested for NaCl sensitivity [54] and hyper-biofilm formation [60], and the complement was confirmed to restore the wild-type phenotype for both. In vitro growth curves to confirm equal growth potential between both DflaA and DkpsM mutant and complemented strains were conducted in MH broth, at 37uC under microaerophilic conditions with samples taken at 6, 24, and 48 hours post inoculation.

Mouse strains and infection experiments
The C57BL/6 (WT), Sigirr 2/2 , Tlr2 2/2 , Tlr2 2/2 /Sigirr 2/2 , Tlr4 2/2 , and Tlr4 2/2 /Sigirr 2/2 mouse strains used in this study were all bred in-house and kept under specific pathogen-free conditions at the Child and Family Research Institute (CFRI). The combined TLR and SIGIRR deficient mice were created by cross breeding single knockout strains as described previously [25]. Mice at 6-10 weeks of age were orally gavaged with 100 ml of a 50 mg/ ml vancomycin solution suspended in PBS (dose per mouse of ,5 mg). Four hours later, each mouse was inoculated with an overnight culture of ,10 7 CFUs of C. jejuni 81-176 or one of the above mentioned mutant strains. The weight of each mouse was recorded before antibiotic treatment and inoculation, and each mouse was weighed again every two days to check for weight loss/ gain. Fecal samples were collected 1, 3, 5 and 7 DPI, were weighed, homogenized, serially diluted and plated onto Campylobacter agar plates containing Karmali selective supplements (Oxoid). Three and seven days post infection, mice were anaesthetized with isofluorane and euthanized by cervical dislocation. The mice were immediately dissected and their ileum, cecum, colon, mesenteric lymph nodes and spleen were isolated. Cecal and proximal colonic tissues were fixed in 10% neutral buffered formalin (Fisher). Cecal tissues were also washed to remove luminal contents and then suspended in RNAlater (Qiagen) for subsequent RNA extraction. The remainder of the cecum (including luminal contents), and other isolated tissue sections were suspended in 1 ml sterile PBS (pH 7.4) for viable cell counts. Tissue samples were homogenized, serially diluted and plated onto Campylobacter agar plates containing Karmali selective supplements (Oxoid). Following 48 hours incubation, at 42uC under microaerobic conditions colonies were enumerated, and the pathogen burden (CFUs/g of tissue) was calculated. Statistically significant differences were determined using a non-parametric Mann-Whitney test, with a p value below 0.05 used as the threshold for significance.
To monitor colonization of C. jejuni over a 25 day timeframe, three experimental groups comprising 13 WT and 15 Sigirr 2/2 mice total were inoculated with C. jejuni 81-176. Weights and fecal samples were taken every two days from 1 DPI to 25 DPI. CFUs present within the fecal samples were enumerated as described above and statistical significance was determined using multiple ttests (p,0.05).

Ethics statement
All animal experiments were performed according to protocol number A11-290, approved by the University of British Columbia's Animal Care Committee and in direct accordance with the Canadian Council of Animal Care (CCAC) guidelines. Mice were monitored for mortality and morbidity throughout their infection and euthanized if they showed signs of extreme distress or more than 15% body weight loss.
The paraffin embedded, formalin-fixed tissue sections were also used for immunofluorescent staining using variations on established protocols [25,61]. Briefly, tissue sections were deparaffinized by heating for 8 minutes, clearing with xylene, rehydrating with 100%, 95%, and 70% ethanol, followed by dH 2 O. Antigen retrieval of the tissue sections was conducted with sodium citrate buffer (pH 6.0), in a steam bath for 30 minutes. Blocking was done with an endogenous Biotin-blocking kit (Molecular Probes) following manufacturer protocols, followed by 1 hour blocking with donkey serum blocking buffer (donkey serum in PBS containing 1% bovine serum albumin (BSA), 0.1% Triton-X100, 0.05% Tween 20, and 0.05% sodium azide). The primary antibodies used were for Actin (goat polyclonal, Santa Cruz Biotechnology), Cytokeratin 19 (goat polyclonal, Santa Cruz Biotechnology), and Campylobacter jejuni (Biotin-rabbit polyclonal, Abcam). Each was visualized using Alexa Fluor 488-conjugated donkey anti-goat IgG (Invitrogen) or Alexa Fluor 568-conjugated streptavidin (Molecular Probes). The tissues were mounted using ProLong Gold antifade reagent containing DAPI (Invitrogen). The stained slides were viewed using a Zeiss AxioImager Z1, photographed using an AxioCam HRm camera with AxioVision software. Confocal imaging was conducted with a Leica TCS SP5 system, using the Leica Application suite software.
Slides stained for C. jejuni and DAPI were used to assess crypt colonization. We used slides of formalin fixed, 7 day infected cecal tissues from WT, Sigirr 2/2 , Tlr2 2/2 /Sigirr 2/2 , and Tlr4 2/2 / Sigirr 2/2 mice to count the number of crypts containing visible numbers of C. jejuni. In total, 264, 146, 140, and 120 crypts were counted for each mouse strain respectively, from three slides each, each of which contained at least three tissue sections.

RNA extraction and quantitative real-time PCR
Tissue samples previously isolated from infected or control mice were preserved in RNAlater at 220uC for later use. RNA was extracted using a Qiagen RNeasy kit (Qiagen) according to the manufacturer's protocol. The final RNA samples were eluted from the columns in sterile, RNAse free dH 2 O and quantified using an ND-1000 spectrophotometer (Nanodrop). cDNA was synthesized from the RNA using an Omniscripts RT kit (Qiagen) and Oligo-dT (Applied Biological Material Inc.). Quantitative real-time PCR was carried out using an MJ mini-opticon Real-Time PCR system (Bio-Rad) using IQ SYBR Green Supermix (Bio-Rad). The primers used have been described previously [25] and are listed in Table S1. Quantification of the qPCR results was performed using Gene Ex Macro OM 3.0 software (Bio-Rad) and ANOVAs were used to determined statistical significance of the results.

HEK TLR reporter cell assays
HEK TLR reporter cell lines, HEK-Blue hTLR2 and HEK-Blue hTLR4, were purchased from InvivoGen (San Diego, CA, USA). HEK-Blue hTLR2 were obtained by co-transfection of hTLR2 and hCD14 co-receptor genes into HEK 293 cells, while HEK-Blue hTLR4 were obtained by co-transfection of hTLR4 and hMD-2/CD14 co-receptor genes. The cells were transfected with the secreted embryonic alkaline phosphatase (SEAP) gene and stably express SEAP under the control of a promoter inducible by NF-kB and activator protein 1 (AP-1). Thus, stimulation of hTLR2 or hTLR4 will lead to the production of extracellular SEAP in the culture medium proportional to the level of NF-kB/AP-1 activation. Cells were grown in High Glucose DMEM (HyClone, Logan, UT, USA) with 2 mM L-glutamine, 10% heat-inactivated FBS (HyClone), 100 mg/ml Normocin (InvivoGen) and selective antibiotics (16HEK-Blue selection, InvivoGen) according to the manufacturer's instructions.
The activation of TLR2 or TLR4 was assessed by measuring the SEAP activity using QUANTI-Blue (InvivoGen) colorimetric assay. The reporter cells (5610 4 /well) were seeded in a 96-well plate (BD Bioscience, Mississauga, ON, Canada). The next day, cells were treated with fresh media (without selective antibiotics) containing wild type, DkpsM, or DkpsM+kpsM C. jejuni strains for 4 h. Cells treated with culture medium only, TLR2 ligand Pam3CSK4 (100 ng/mL, InvivoGen) and TLR4 ligand lipopolysaccharide (LPS, Escherichia coli K-12, 100 ng/mL, In-vivoGen) serve as the negative and positive controls, respectively. For each experiment, all conditions were done in triplicate. After 4 h incubation, culture media were collected and centrifuged to remove bacteria. The supernatants (20 ml) were then incubated with QUANTI-Blue solution (180 ml) in a 96well flat-bottom plate at 37uC for 16-18 h to allow the color development. The color change of the substrate solution corresponds to the activation of NF-kB/AP-1, which can be quantified by optical density (l = 655 nm) measurement using a SpectraMax 384 Plus plate reader (Molecular Devices, Sunnyvale, CA, USA). Figure S1 Colonization of WT and Sigirr2/2 mouse ileum, colon and systemic sites by C. jejuni 81-176, 3 and 7 DPI. CFUs/g of C. jejuni 81-176 recovered from the ileum (A), colon (B), Mesenteric lymph nodes (MLN) (C), Spleen (D, fecal samples (E and F) and of infected mice. Relatively low and inconsistent numbers were recovered from the ileum of infected mice, while numbers comparable to the cecum were recovered from the colons. No significant difference was detected between WT and Sigirr 2/2 mice. n = 10 or 11 WT mice, and 12 or 13 Sigirr 2/2 mice for 3 and 7 DPI respectively. (TIF) Figure S2 Relative bacterial composition, before and after vancomycin treatment. Bacterial composition of mouse fecal samples taken before and after vancomycin treatment, and uninfected and infected with C. jejuni 81-176, as measured by qRT-PCR. Primers were specific to the major phyla Bacteroidetes and Firmicutes, as well as all Eubacteria, and the % of Bacteroidetes or Firmicutes was calculated relative to the total Eubacteria for each sample. The ratio of Bacteroidetes to Firmicutes shifted dramatically following vancomycin treatment (.40% to ,1%), with the Bacteroidetes being reduced from the dominant phylum, to barely measurable quantities. However, no significant differences were noted between WT and Sigirr 2/2 mice under uninfected conditions or following infection with C. jejuni 81-176. (TIF) Figure S3 Four week C. jejuni infection of WT and Sigirr2/2 mice. (A) CFUs of C. jejuni 81-176 recovered from the fecal samples of WT and Sigirr 2/2 mice over a period of 25 days, with fecal sampling taking place every two days from 1 DPI to 25 DPI. The experiment was repeated 3 times, for a total of 13 WT mice and 15 Sigirr 2/2 mice. The data displayed here is a representative experiment of the three, showing data from 4 WT and 8 Sigirr 2/2 mice. Slight differences between the clearance time between experiments led to higher variability at later time points between experiments, but results were consistent within each experiment. Colonization peaks at 7-9 DPI, then CFUs recovered from all the Sigirr 2/2 mice rapidly decline, with roughly half the Sigirr 2/2 mice clearing the infection by 23 DPI. WT mice did not exhibit any drop in pathogen burden by 25 DPI. A statistically significant difference between CFUs recovered from WT and Sigirr 2/2 mice (p,0.05) was measured between 13 and 25 DPI as determined by multiple t-tests. (B) The % change in mouse weight relative to their weight pre-inoculum over 25 days. No significant difference was found between WT and Sigirr 2/2 mice (p.0.05). n = 13 WT, 15 Sigirr 2/2 mice. (TIF) Figure S4 Macroscopic images of mouse intestines infected by C. jejuni. Images of the ceca and colons of mice colonized by C. jejuni 81-176, 3 DPI. The WT mouse did not show any outward signs of inflammation and was largely indistinguishable from that of an uninfected mouse. The infected Sigirr2/2 mice show an enlargement of the mesenteric lymph nodes adjacent to the cecum and signs of inflammation around the cecum and proximal colon, but no signs of infection into the distal colon, or ileum. The Tlr2 2/2 /Sigirr 2/2 mice show a shrinkage of the cecum and colon, with no luminal content apparent. The mesenteric lymph nodes are enlarged, but the ileum still shows no outward signs of inflammation. The Tlr4 2/2 /Sigirr 2/2 mice show few signs of inflammation, but the cecum is often slightly enlarged, with more fluid contents. (TIF)  Figure S6 Histology of TLR single knockouts. H&E staining of formalin-fixed, paraffin-embedded cecal tissues of Tlr2 2/2 and Tlr4 2/2 mice 3 and 7 DPI. Neither mouse strain developed significant pathology 3 DPI, despite colonization comparable to their SIGIRR double knockout counterpart. At 7 DPI, the Tlr4 2/2 mice continued to show no pathology, while the Tlr2 2/2 mice did start to show signs of pathology, similar to their Tlr2 2/2 /Sigirr 2/2 counterpart. (TIF) Figure S7 Cytokine expression in mice infected with C. jejuni DkpsM. (A-H) qRT-PCR conducted on RNA extracted from the ceca of control or mice infected with C. jejuni DkpsM. Controls are the pooled results of 3, vancomycin pre-treated, but uninfected mice, euthanized 3 days post-treatment. All infected mice represent the average results of 2 independent experiments, each of which include the pooled RNA of 3-5 mice, euthanized either 3 or 7 DPI. Few mice exhibited elevated cytokine expression 3 DPI, however, expression was significantly higher in Sigirr 2/2 and Tlr2 2/2 /Sigirr 2/2 mice 7 DPI. Statistical significance was determined using a One way ANOVA with a Bonferroni post-test. * p,0.05 relative to WT (B6) or Sigirr 2/2 uninfected control mice. ** p,0.05 relative to the infected WT (B6) mice euthanized on the same DPI in addition to the uninfected control mice. (TIF)

Supporting Information
Table S1 Primers used in this study were developed for this study or derived from previously published studies.